• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

About FDA

  • Print
  • Share
  • E-mail

Staff

 Christine Moore, Ph.D., Acting Director

Phone:

(301) 796-1900

Fax

(301) 796-9748

Email: 

Christine.Moore@fda.hhs.gov

U.S. Mail: 

10903 New Hampshire Avenue HFD-800
Silver Spring, MD 20993

Dr. Moore is the Acting Office Director and Deputy Director for Science and Policy for FDA's Office of New Drug Quality Assessment. She started at the agency in 2004 as the Branch Chief of the newly created Manufacturing Science group. Christine has been actively involved in FDA's Quality by Design efforts and was a member of the expert working group for ICH Q8(R). Prior to joining the FDA, she worked for 10 years in API process development and scale-up at Pfizer and Searle/Pharmacia. Her background is in chemical and biochemical engineering, with degrees from Northwestern University and Massachusetts Institute of Technology.

 

Scott Furness, Ph.D., Deputy Office Director for Review and Operations 

Phone:

(301) 796-1900

Fax

(301) 796-9748

Email: 

Michael.Furness@fda.hhs.gov

U.S. Mail: 

10903 New Hampshire Avenue HFD-800
Silver Spring, MD 20993

Dr. Scott Furness is currently the Deputy Office Director for Review and Operations in the Office of New Drug Quality Assessment at the US Food and Drug Administration. Prior to joining ONDQA in 2013, he served as the Director of the Division of Nonprescription Regulation Development (DNRD), in the Office of New Drug (OND) Office of Drug Evaluation IV (ODE IV, formerly the Office of Nonprescription Products). Prior to joining ODE IV in 2007, Scott served as a Chemistry Reviewer and Team Leader in the Office of Generic Drugs (OGD). Scott has coauthored a number of peer-reviewed publications relating to Pharmaceutical Solid Polymorphism and Impurities.  Before coming to FDA/CDER in 2000, Scott was an NIH Postdoctoral Fellow in the Laboratory of Medicinal Chemistry in the National Institute of Diabetes and Digestive and Kidney Diseases. While at NIH, he worked on the design, synthesis, and pharmacological evaluation of molecules directed at various central and peripheral drug receptors. Scott received his undergraduate degree in chemistry from Virginia Tech and his Ph.D. in synthetic organic chemistry from the University of Georgia.

 

Richard (Rik) Lostritto, Ph.D., Acting Deputy Office Director for Science and Policy 

Phone:

(301) 796-1900

Fax

(301) 796-9748

Email: 

Richard.Lostritto@fda.hhs.gov 

U.S. Mail: 

10903 New Hampshire Avenue HFD-800
Silver Spring, MD 20993

Richard (Rik) Lostritto, Ph.D., joined the FDA in 1995 and currently serves as Acting Deputy Office Director for Science and Policy and Acting Biopharmaceutics Lead in the Office of New Drug Quality Assessment (ONDQA). Previously, Rik served as Director, Division-I which includes CMC (chemistry, manufacturing, and controls) responsibility for oncology, hematology, cardio-renal, neurology, and psychiatric drug products. He had also served as CMC Team Leader successively collocated in the Divisions of Oncology Drug Products and Pulmonary and Allergy Drug Products. Before joining the Agency, Dr. Lostritto worked at Boehringer Ingelheim Pharmaceuticals leading a group which developed medical aerosol formulations after serving as Assistant / Associate Professor of Pharmacy at The University of Connecticut (1983-1992). He received his M.S. and Ph.D. Degrees in Pharmaceutical Chemistry and Pharmaceutics from the University of Michigan and his B.S. Degree in Pharmacy from The University of Connecticut.